John C. Byrd, MD

Dr. Byrd on Future Directions With Acalabrutinib in CLL

June 30th 2021

John C. Byrd, MD, discusses future directions with acalabrutinib in chronic lymphocytic leukemia.

Dr. Byrd on the Clinical Implications of the ELEVATE-RR Trial in CLL

June 16th 2021

John C. Byrd, MD, discusses the clinical implications of the phase 3 ELEVATE-RR trial in chronic lymphocytic leukemia.

Dr. Byrd on the Rationale for the ELEVATE-RR Trial in CLL

June 10th 2021

John C. Byrd, MD, discusses the rationale for the phase 3 ELEVATE-RR trial in chronic lymphocytic leukemia.

Dr. Byrd Discusses the Prognosis of Patients With CLL

April 28th 2018

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the prognosis of patients with chronic lymphocytic leukemia.

Dr. Byrd on Challenges Facing CLL

April 6th 2018

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the challenges facing the field of chronic lymphocytic leukemia (CLL).

Dr. Byrd Discusses the Future Treatment of CLL

March 23rd 2018

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the future treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Byrd on Combination Strategies in CLL

March 5th 2018

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the role of combinations in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Byrd on Impact of Ibrutinib on Patients With CLL

September 6th 2017

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the long-term impact that ibrutinib (Imbruvica) has on patients with chronic lymphocytic leukemia (CLL).

Dr. Byrd on Long-term Safety Data With Ibrutinib in CLL

August 17th 2017

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses long-term safety data with ibrutinib (Imbruvica) as treatment for patients with chronic lymphocytic leukemia (CLL).

Dr. Byrd on Updated RESONATE Findings in CLL

August 10th 2017

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of Medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the updated findings of the RESONATE trial in chronic lymphocytic leukemia (CLL).

Dr. John Byrd on Ibrutinib in CLL

August 9th 2016

Dr. Byrd on Alacabrutinib's Mechanism of Action in CLL

July 8th 2016

John Byrd, MD, director of the Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center, discusses the mechanism of acalabrutinib, a next-generation BTK inhibitor as a potential treatment for patients with chronic lymphocytic leukemia.

Dr. John Byrd on Challenges in CLL

June 21st 2016

Dr. Byrd on Ibrutinib's Impact on Treatment Landscape in CLL

March 21st 2016

John Byrd, MD, director of the Division of Hematology, Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, discusses the RESONATE 2 study, which looked at ibrutinib versus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia (CLL).

Dr. John Byrd Discusses the Treatment Landscape for CLL

September 9th 2014

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, discusses the promising treatment landscape for patients with chronic lymphocytic leukemia.

Dr. Byrd on Ibrutinib Versus Ofatumumab in CLL

June 1st 2014

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, discusses the promising findings from the phase III RESONATE trial that compared ofatumumab to ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

Dr. Byrd Provides an Update on Ibrutinib in CLL

January 2nd 2014

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), provides an update on ibrutinib for the treatment of CLL.

Dr. John Byrd on Bruton's Tyrosine Kinase in CLL

January 29th 2013

John C. Byrd, MD, director of the division of hematology at The Ohio State University Comprehensive Cancer Center, discusses the role of Bruton's Tyrosine Kinase (BTK) in chronic lymphocytic leukemia.

Dr. John Byrd Discusses Ibrutinib in CLL

December 8th 2012

John C. Byrd, MD, director of the division of hematology at The Ohio State University Comprehensive Cancer Center, discusses the new and updated results of a phase Ib/II study involving ibrutinib at the ASH Annual Meeting and Exposition.